Based on its updated timetable, AB Science says it anticipates the CHMP's decision on its marketing authorization application for its masitinib in ALS (amyotrophic lateral sclerosis) in the first quarter of 2024.

For regulatory reasons, the biopharmaceutical company requested an extension to the suspension of proceedings, which was granted at the CHMP (Committee for Medicinal Products for Human Use) session of September 11-14.

Based on the current stage of work in progress, AB Science is confident that the current manufacturing process for masitinib complies with the new European Medicines Agency directive.

Copyright (c) 2023 CercleFinance.com. All rights reserved.